A recent study demonstrated the real-world effectiveness and tolerability of a targeted agent for the treatment of relapsed or refractory mantle cell lymphoma.
Dawn Holcombe, MBA, FACMPE, ACHE, explains why private payers are making the transition from traditional reimbursement models to value-based models at a slow pace and how OCM performance results may impact this transition.
Many physicians still mistakenly believe that hospice and palliative medicine are one and the same, according to Timothy W Holder, MD, medical director, supportive care and survivorship, Cancer Treatment Centers of America.
Thomas Marsland, MD, medical oncology, St Joseph Health (Petaluma, CA), discusses the many considerations related to initial therapy, transplantation, maintenance, and salvage therapy for patients with multiple myeloma.
In a study to test the efficacy of the ASCO Patient-Centered Oncology Payment model, hospitalizations during the active treatment period for ovarian cancer were expected to decrease by what percentage?
Referral of newly diagnosed adolescent patients with acute lymphoblastic leukemia to pediatric and National Cancer Institute-designated centers should be strongly recommended.
Medicare will pay hospitals close to its standard mark-up rate for administering cell therapy Yescarta for cancer outpatients, who will have a co-payment of nearly $80,000.
A continuing medical education session at the Society of Gynecologic Oncology’s 2018 Annual Meeting on Women’s Cancer offered insight for optimal selection and administration of PARP inhibitors, as well as homologous recombination deficiency testing in ovarian cancer.

By Will Boggs MD

NEW YORK (Reuters Health) - Outcomes in patients with localized renal masses are favorable in those who choose active surveillance over immediate surgery, according to a database study.

From 2007 to 2014, funding from the National Cancer Institute for ovarian and uterine cancers fluctuated by what percentage?